BRPI1014086A2 - produtos farmacêuticos peptídeos para liberação nasal - Google Patents

produtos farmacêuticos peptídeos para liberação nasal

Info

Publication number
BRPI1014086A2
BRPI1014086A2 BRPI1014086-7A BRPI1014086A BRPI1014086A2 BR PI1014086 A2 BRPI1014086 A2 BR PI1014086A2 BR PI1014086 A BRPI1014086 A BR PI1014086A BR PI1014086 A2 BRPI1014086 A2 BR PI1014086A2
Authority
BR
Brazil
Prior art keywords
pharmaceuticals
fatty acid
nasal
release peptides
active agents
Prior art date
Application number
BRPI1014086-7A
Other languages
English (en)
Inventor
Stern William
Original Assignee
Unigene Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigene Laboratories Inc. filed Critical Unigene Laboratories Inc.
Publication of BRPI1014086A2 publication Critical patent/BRPI1014086A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

produtos farmacêuticos peptídeos para liberação nasal. a presente invenção refere-se a produtos farmacêuticos para administração nasal que contêm agentes ativos peptídeos e são formulados com compostos que aperfeiçoam biodisponibilidade dos agentes ativos peptídeos. em particular, citratos, ácidos graxos, ésteres de açúcar de ácidos graxos ou acil carnitinas são usados. em algumas modalidades, um éster de açúcar de um ácido graxo é usado em combinação com um ácido graxo, ou alternativamente, uma acil carnitina.
BRPI1014086-7A 2009-04-02 2010-03-30 produtos farmacêuticos peptídeos para liberação nasal BRPI1014086A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16616009P 2009-04-02 2009-04-02
US61/166,160 2009-04-02
US12/732,081 2010-03-25
US12/732,081 US20100256060A1 (en) 2009-04-02 2010-03-25 Peptide pharmaceuticals for nasal delivery
PCT/US2010/029187 WO2010114830A1 (en) 2009-04-02 2010-03-30 Peptide pharmaceuticals for nasal delivery

Publications (1)

Publication Number Publication Date
BRPI1014086A2 true BRPI1014086A2 (pt) 2019-02-26

Family

ID=42826690

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014086-7A BRPI1014086A2 (pt) 2009-04-02 2010-03-30 produtos farmacêuticos peptídeos para liberação nasal

Country Status (9)

Country Link
US (1) US20100256060A1 (pt)
EP (1) EP2413857A4 (pt)
JP (1) JP2012522787A (pt)
KR (1) KR20120004981A (pt)
CN (1) CN102378605A (pt)
AU (1) AU2010232756A1 (pt)
BR (1) BRPI1014086A2 (pt)
CA (1) CA2754593A1 (pt)
WO (1) WO2010114830A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457086B2 (en) * 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
KR20220091825A (ko) 2020-12-24 2022-07-01 양주은 돝섬 보드게임

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
AU783952B2 (en) * 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
EP1758927A4 (en) * 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
AU2006343306A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US20110046058A1 (en) * 2009-08-24 2011-02-24 Aegis Therapeutics Llc Compositions for enteral absorption and sustained action of leptin-related peptides useful in the treatment of obesity and leptin-modulated disease

Also Published As

Publication number Publication date
CA2754593A1 (en) 2010-10-07
US20100256060A1 (en) 2010-10-07
JP2012522787A (ja) 2012-09-27
CN102378605A (zh) 2012-03-14
WO2010114830A1 (en) 2010-10-07
EP2413857A1 (en) 2012-02-08
KR20120004981A (ko) 2012-01-13
EP2413857A4 (en) 2014-03-05
AU2010232756A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
BR112013023847A2 (pt) composições farmacêuticas compreendendo ésteres de sorbitano
ES2496091T3 (es) Composiciones de neutralización de malos olores que comprenden ácido undecilénico o ácido cítrico
PH12015500936A1 (en) Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same
BR112013031268A8 (pt) polipeptídeos
BR112014031837A2 (pt) formulações de progesterona
PH12014500449B1 (en) Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
BR112013033364A2 (pt) conjunto para manipular um osso que compreende um sistema de rastreamento de posição
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
IL219874A0 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2009139589A3 (en) Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
MX369477B (es) Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación.
MX344269B (es) Productos nutricionales que incluyen un sistema de grasa que incluye acidos grasos libres.
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BRPI0923004A2 (pt) processo para a preparação de hlc de éster etílico de ácido trans 4-amino-ciclohexil acético
BRPI1014086A2 (pt) produtos farmacêuticos peptídeos para liberação nasal
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
UA96156C2 (ru) Эфиры докозагексаеновой кислоты и их применение для лечения и предупреждения сердечнососудистого заболевания
CL2012002560A1 (es) Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).
IN2014CN03214A (pt)
NZ609640A (en) Treatment of mecp2-associated disorders
WO2008115069A3 (en) Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents
BR112012021445A2 (pt) formulação farmacêutica ou neutracêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]